The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Beyond Addiction: Medical Therapy for Addiction May Benefit Medical Adherence

Beyond Addiction: Medical Therapy for Addiction May Benefit Medical Adherence

June 17, 2019 • By Thomas R. Collins

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Naltrexone, an opioid antagonist, is used to decrease cravings in both alcohol use disorder and opioid use disorder. It also dampens the effects of opioids. When used to treat opioid use disorder, the patient needs to be completely opioid free before taking it, or naltrexone may cause withdrawal. The injectable form of naltrexone lasts 30 days and better enables adherence than the oral form. But it isn’t free of adherence concerns, because a patient may not show up for their next injection, Dr. Stoller acknowledged. Also, patients can still become impaired using alcohol, but it won’t feel good, he notes.

You Might Also Like
  • Addiction Therapy Is Underprescribed but May Benefit Medical Adherence
  • U.S. to Promote Use of Opioid Alternatives to Treat Addiction
  • U.S. FDA Approves First-Ever Implant to Treat Opioid Addiction
Also By This Author
  • When Symptoms of Rheumatic Disorder Point to Endocrine Disease

Methadone, for opioid use disorder, is a full-opioid agonist that—depending on the dose—treats withdrawal, reduces craving and blocks the effect of taking an opioid. It can only be given at one of the roughly 1,600 opioid treatment programs in the U.S.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Rheumatologists with patients in the hospital who are on methadone have to coordinate with these programs upon treatment admission, throughout the admission and especially upon discharge, because methadone cannot be prescribed by a discharging physician.

Methadone is the most highly regulated medication in medicine, Dr. Stoller said. Treatment programs have to provide services as supervised dosing, allowing patients to earn take-home doses; counseling; and drug testing; and assistance to meet other rehabilitation goals.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

“The quality and quantity of services can vary across opioid treatment programs, so there may be some in your area that provide more comprehensive treatment that you’d want to direct patients to,” he said. Patients who use sedatives, such as benzodiazepines, can still be sedated, “so it’s important to pay attention to those abuse problems, as well.”

Although science has demonstrated good outcomes for patients taking methadone for decades, the drug still suffers from false perceptions. It’s often seen as a crutch or as substituting one drug for another, Dr. Stoller said.

He cautioned that patients on methadone get an analgesic effect for only a few hours and may still need pain medication. These patients may even need opioids after a substantial injury or post-surgically—and possibly a higher-than-normal dose due to cross-tolerance.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Stoller also cautioned against short-term treatment with methadone. “If somebody goes off of these medications within a year, there’s a very high likelihood of relapse,” he said. “The problem is, after you are off of these … agonist medications, the person is much more susceptible to overdose.”

Buprenorphine, another opioid use disorder treatment, is a partial agonist with a ceiling to its respiratory depressive effects, making it safer. Its formulation discourages diversion to illicit use by crushing pills. An analysis of data from Massachusetts found treating addition with buprenorphine or methadone led to lower monthly Medicaid costs, fewer relapses and a lower mortality rate, Dr. Stoller said.1

Pages: 1 2 3 | Single Page

Filed Under: Conditions Tagged With: Addiction, addiction treatment, Opioid abuse, Opioids

You Might Also Like:
  • Addiction Therapy Is Underprescribed but May Benefit Medical Adherence
  • U.S. to Promote Use of Opioid Alternatives to Treat Addiction
  • U.S. FDA Approves First-Ever Implant to Treat Opioid Addiction
  • U.S. Lets More Healthcare Workers Prescribe Opioid Addiction Treatment

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)